Compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system
View Patent ↗Described are novel salts of the compound (3R,4R,5S)-5-(difluoromethyl) piperidine-3,4-diol, as well as methods of using the same for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease and/or Parkinson's disease.
1. A crystalline form of (3R,4R,5S)-5-(difluoromethyl)piperidine-3,4-diol•fumarate (1:1), wherein the crystalline form has an X-ray diffraction pattern comprising characteristic peaks at:
2-Theta (Degrees)
11.70 ± 0.2
15.70 ± 0.2
20.78 ± 0.2
21.46 ± 0.2
27.74 ± 0.2.
2. The crystalline form of claim 1 having an X-ray diffraction pattern comprising characteristic peaks at:
2-Theta (Degrees)
11.70 ± 0.2
14.66 ± 0.2
15.70 ± 0.2
19.34 ± 0.2
20.78 ± 0.2
21.46 ± 0.2
22.22 ± 0.2
26.26 ± 0.2
26.90 ± 0.2
27.74 ± 0.2.
3. A crystalline form of (3R,4R,5S)-5-(difluoromethyl)piperidine-3,4-diol•fumarate (1:1) having an X-ray diffraction pattern of FIG. 1 .
4. A pharmaceutical composition comprising the crystalline form of claim 1 and at least one pharmaceutically acceptable carrier.
5. A crystalline form of (3R,4R,5S)-5-(difluoromethyl)piperidine-3,4-diol•fumarate (1:1) made by a process comprising:
preparing a solution comprising (3R,4R,5S)-5-(difluoromethyl)piperidine-3,4-diol, fumaric acid and a solvent, wherein the solvent is ethanol, ethyl acetate, ethyl formate, acetone, 2-butanone, dichloromethane, tetrahydrofuran, water or acetonitrile; and
crystallizing the (3R,4R,5S)-5-(difluoromethyl)piperidine-3,4-diol•fumarate (1:1) from the solution.
6. The crystalline form of claim 5 , wherein the solvent includes one or more of ethanol and water.